Paganini 1991.

Methods	Study design: RCT Study duration: NS Duration of follow‐up: 27 to 38 weeks
Participants	Country: USA Setting: 6 centres Stable HD patients; IV EPO > 3 years Number: treatment group 1 (25); treatment group 2 (33) Mean age ± SD (years): NS Sex (M/F): NS Exclusion criteria: NS
Interventions	Treatment group 1 EPO: SC once/wk Mean weekly dose at baseline: 254 ± 198 U/kg Treatment group 2 EPO: 3 times/wk Co‐interventions Iron and folic acid
Outcomes	HCT at the end of the study EPO dose at end of study
Notes	Abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NS
Allocation concealment (selection bias)	Unclear risk	NS
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding, unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No blinding but outcome of Hb unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if all patients completed the study
Selective reporting (reporting bias)	Unclear risk	No report of mortality or adverse effects
Other bias	Unclear risk	No information